Log In
Print
BCIQ
Print
Print this Print this
 

IT-139 (formerly NKP-1339)

  Manage Alerts
Collapse Summary General Information
Company Intezyne Technologies Inc.
DescriptionTransferrin targeted ruthenium-based small molecule that downregulates GRP78
Molecular Target Heat shock 70 kDa protein 5 (glucose-regulated protein, 78kDa) (HspA5) (GRP78)
Mechanism of Action 
Therapeutic ModalitySmall molecule

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$12.4M

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today